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Valproic acid and its derivatives are commonly used to treat many psychiatric conditions in the elderly. Hyperammonemia is a less
common but important side eﬀect of these drugs. The elderly patient appears highly vulnerable to this side eﬀect of this group of
medications. In this paper, we systematically review the published literature for hyperammonemia induced by valproic acid and
its derivatives. We describe the three reported cases and review possible treatment strategies for this condition.
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1.Introduction
Valproic acid is a broad-spectrum antiepileptic drug that
is approved for the treatment of several types of seizures.
It is also prescribed for the treatment of bipolar disorder,
schizoaﬀective disorder, social phobias, neuropathic pain,
andfortheprophylaxisandtreatmentofmigraineheadaches
[1]. Valproic acid and its derivatives have been found to
be useful and generally safe in the treatment of bipolar
aﬀective disorder, agitation in dementia, and refractory
anxietydisordersintheelderly[2–4].Thesedrugsareknown
to cause hyperammonemia and associated encephalopathy,
butmostofthisdatacomesfromchildrenandyoungeradults
[5–10]. However, recent case reports have highlighted the
fact that this complication can also occur in elderly [4, 11,
12]. In this paper, we review the published literature on the
occurrence of valproic acid-induced hyperammonemia in
the elderly.
2. Ammonia, Hyperammonemia,and
HyperammonemicEncephalopathy
Amino acids, products of protein breakdown, are usually
metabolized in the liver by transaminases and oxidative
deaminases to produce ammonia [13]. Ammonia is then
converted to urea and excreted through the kidney. The most
important enzyme in the incorporation of ammonia into the
urea cycle is carbomylphosphatase synthetase I (CPS I) [14].
Ammonia is also produced in the kidneys by the conversion
of glutamine to glutamate by the enzyme glutaminase [11].
Hyperammonemia is a condition characterized by eleva-
tion in the serum level of ammonia above 40mmols/L [15].
It is commonly caused by liver disease or inborn errors of
metabolism [16]. Other less common causes are hyperinsu-
linemichypoglycemia,carnitinedeﬁciency,malignancieslike
leukaemias and myelomas, portosystemic shunts, urinary
infections, surgeries, and parenteral nutrition [12, 13, 17–
20]. Medications like 5-ﬂuorouracil, salicylate, asparaginase,
acetazolamide, diuretics, and valproic acid and its derivates
have also been implicated in the development of this condi-
tion [5, 21–24]. However, an elevation in serum ammonia
level above 200mmols/L is more commonly seen in inborn
errors of metabolism like urea cycle defects and branch chain
organic acidaemias, although rarely other conditions may
cause such high blood levels [25]. Although, hyperammone-
mia is thought to be associated with liver disease, most cases
present with normal liver function [10, 26].
Mild and transient hyperammonemia can often be
asymptomatic and is usually triggered by protein loads and
catabolic states [13]. In symptomatic cases, the clinical fea-
tures may be variable and episodic [13]. Many cases present
with acute mental status changes characterized by confusion,
personality change, irritability, ataxia, visual disturbance,
lethargy, and somnolence [13]. They may also present with
nausea, vomiting, or hyperventilation. More severe cases
can lead to encephalopathy characterized by stupor and2 Case Reports in Medicine
coma [27–30]. Although, most patients recover even from
multiple episodes of hyperammonemic encephalopathy, it
may occasionally lead to brain damage [31–33]. In severe
untreated cases, seizures and death can occur due to raised
intracranial pressure [13].
The pathogenesis of hyperammonemic encephalopathy
remains unclear. Changes in mental status are thought to
be due to high levels of ammonia and the presence of
other organic acids. The brain ammonia concentration can
be high even when the serum ammonia level is normal
[5]. Hyperammonemia can also cause encephalopathy by
inhibition of glutamate uptake by astrocytes [14, 34, 35].
As with delirium, elderly patients may present with several
concomitant predisposing factors for developing hyperam-
monemia and encephalopathy [4, 36]. These include age-
related cerebral changes like a more permeable blood brain
barrier, alterations in stress-regulating neurotransmitters,
and intracellular signal transduction systems [4, 36]. Other
risk factors include multiple medical problems, such as renal
failure or hypoalbuminemia, or concomitant administration
of topiramate, cimetidine, and aspirin, that may elevate
the free fraction of valproate and increase the risk of
hyperammonemia even in the absence of metabolic defect in
the urea cycle [4]. With age, protein binding and certain liver
functions decrease, leading to decreased plasma albumin,
hepatic oxidation, and hepatic cytochromes such as P-
450-3A4 [4]. Concomitant administration of antiseizure
medications such as phenytoin and phenobarbital may also
increase the risk of hyperammonemia and should be used
with caution [4]. In order to reduce the morbidity and
mortality from this condition, vigilance for risk factors, early
diagnosis, and prompt treatment are paramount [14].
It has been found that routine laboratory investigations
are often not helpful in the diagnosis [13]. Although
higher ammonia levels are associated with encephalopathy,
blood levels of ammonia do not often correlate with the
clinical condition [37]. It is important to ensure that serum
ammonialevelsareaccuratelymeasuredasfaultystorageand
transport can lead to hemolysis and erroneous elevations
in serum ammonia level [13]. Heparinised venous samples
should be obtained and specimens should promptly be sent
to the laboratory on ice or in a vacuum tube [13].
In patients with encephalopathy, cerebrospinal ﬂuid
(CSF) glutamine levels and EEG may aid in the diagnosis.
A study of seven patients, ages 17–58 years, with valproate
induced hyperammonemic encephalopathy (VHE), showed
that elevation of CSF glutamine and the changes in the
EEG correlated moderately well with the time course of the
encephalopathy [14]. All patients had medically refractory
seizures.Fivepatientshadbeeninitiatedonvalproatetherapy
shortly before developing signs and symptoms of VHE.
Three of these patients had previously taken valproate
without substantial adverse eﬀects and two had never before
received valproate. Two other patients had taken valproate
for an extended period, but received a dosage increase before
theonsetofVHE.Doseofvalproaterangedfrom500mg/day
to 6500mg/day, although the doses of valproate for 2 of
the cases were uncertain. The valproate levels varied from
33–199mg/dL and the ammonia levels were between 19–
750mmols/L). All patients in the study had EEG changes
showing slow background waves with or without triphasic
waves. CSF glutamine level was elevated in 80% of the
patients with only 71% of patients having an elevated venous
ammonia level. CT scan or MRI may aid in the diagnosis
of encephalopathy [38]. These studies may reveal cerebral
edema,althoughthisisnotaveryconsistentﬁnding[39–41].
3. Methods
We searched the following databases: Ovid MEDLINE
(http://gateway.tx.ovid.com/gw2/ovidweb.cgi) from 1950 to
June Week 3 2009, EBM Reviews—Cochrane Database of
Systematic Reviews 2nd Quarter 2009, PsycINFO 1967 to
June Week 3 2009 with keywords “divalproex sodium,” “val-
proate,” “valproic acid,” and “divalproate,” “hyperammone-
mia,” “hepatic encephalopathy,” “urea cycle disorder,” “liver
failure,” “aged,” and “elderly.” For the purpose of this paper,
we considered anyone over the age of 60 years as “aged”
or “elderly.” We only considered reports from peer reviewed
Englishlanguagejournalsforthisreview.Forstandardization
purpose, we used micromols/liter (mmols/L) for ammonia
level and milligrams/deciliter (mg/dL) for valproic acid level.
Also, the terms “valproic acid” and “valproate” have been
used synonymously.
4. Results
Most of the reported cases of valproate induced hyper-
ammonemia are in children and younger adults. To date,
there are only four reported cases of hyperammonemia
in the elderly in the medical literature [4, 11, 12, 42].
Three major trials using valproic acid and its derivatives
for the treatment of behavioral disturbance in dementia
did not report hyperammonemia as a side eﬀect. In these
trials, sedation and urinary tract infection occurred more
frequently in patients treated with valproic acid than in
controls. Due to the diﬀerences in identifying adverse eﬀects
it was not possible to pool other observations concerning
adverse eﬀects between these studies [42].
The ﬁrst reported case involved an 88-year-old African
American man who presented with confusion after being
treated with valproate at 250mg qid for seizure disorder
of unknown etiology [4]. He had high ammonia levels
(836mmols/L) despite normal liver function tests and val-
proatelevel(48mg/dL).Theconfusionresolvedoncethatthe
valproate was discontinued and phenytoin was started. The
confusion returned once that the valproate was reinitiated at
250mg po qid. The ammonia level during the second trial
was 130mmols/L and it decreased to 60mmols/L once the
valproate was discontinued.
McCall and Bourgeois reported a case in a 62-year-
old person with brain aneurysm repair resulting in seizure
disorder and being treated with divalproex sodium 250mg
tid [12]. The patient presented with a one-week history
of confusion, mumbling speech, dizziness, lethargy, and
weakness. The valproate levels were within normal range
at 75mg/L. The CT scan revealed increased size of theCase Reports in Medicine 3
ventricles, sulci, and cisternal spaces with volume loss—
mildly prominent for age. Ammonia levels were elevated
at 99mmols/L. The urinalysis and blood tests were within
normal levels. The next day, the valproate was stopped and
within next 3 days the patient’s mental status improved.
No other medication was used to reduce the ammonia
level.
The third case involved a 76-year-old white woman with
a seizure disorder who was taking divalproex sodium at
750mg po tid [11]. She presented to the emergency room
two months after treatment was initiated with divalproex,
with a one week history of generalized weakness, confusion,
nausea, and vomiting. She had normal liver function tests.
The discontinuation of the divalproex sodium reduced the
ammonia level from 211mmol/L to 34mmol/L within 11
days. The patient’s mental status and physical functioning
improvedsigniﬁcantlyafterthedivalproexwasdiscontinued.
She was then treated with gabapentin at 300mg po bid for
her seizure disorder.
The fourth case involved a 76-year-old man with bipolar
illness who had been successfully treated with divalproex
for the past 11 years and with extended-release divalproex
for the past 16 months. He had consistently done well,
serum valproic acid level was generally in the 50 to 80mg/dL
range, and transaminases were never elevated. There was
no evidence of delirium or other problems attributable to
divalproex; there had been 1 normal serum ammonia level
4 years ago. He became acutely confused, lethargic, and
near-mute; he also began to urinate on the ﬂoor and to
repeatedly remove his prosthetic eye. He was admitted with
a serum ammonia level of 214mmols/L. Serum valproic
acid level was 73mg/dL, and transaminases and liver
ultrasound were normal. No other source of delirium was
found. Divalproex was discontinued and he was treated with
lactulose, the delirium cleared, serum ammonia normalized
within 72 hours, and he was discharged. The author
indicates that the reasons for this patient’s encephalopathy
remain unclear as there were no medication changes, no
divalproex dosage adjustments, no evidence of liver disease,
and no dietary change. This report underscores the fact that
hyperammonemic encephalopathy is not necessarily an early
complication of valproate therapy [42].
5. Discussion
Theriskfactorsforthedevelopmentofvalproicacid-induced
hyperammonemia include higher doses of the medication,
concomitant use of other antilepiliptics like topiramate,
carnitine deﬁciency, and the presence of congenital abnor-
malities of urea cycle [5, 12, 22, 24, 43] .T h em a l et of e m a l e
ratio appears to be equal, although conclusive data is lacking
a tt h i st i m e[ 44].
Themechanismbywhichvalproicacidanditsderivatives
produce hyperammonemia is unclear, although various
mechanisms have been proposed [45]. In the kidney, these
drugs can increase the transport of glutamine across the
mitochondrial membrane, thus making it available for the
productionofammonia[46].Furthermore,valproicacidcan
stimulate the enzyme glutaminase to increase the conversion
of glutamine to glutamate, thereby making it more available
for the production of ammonia [24, 45, 47, 48].
Valproic acid and its derivatives are also thought to
inhibit the enzyme, Carbamoylphosphate synthetase I (CPS
I),therebypreventingtheincorporationofammoniaintothe
urea cycle [4, 5, 24, 30, 45, 49]. These drugs may inhibits N-
acetylglutamate, an activator of CPS I, that is, needed for the
normal function of this enzyme [50, 51]. They can increase
the concentration of pyruvate, a potent inhibitor of CPS I
which prevents the incorporation of ammonia into the urea
cycle [3, 4, 24, 30, 45, 49].
Carnitine animportantnutrientfoundinmeatanddairy
products is also essential for the metabolism of valproic
acid [52]. Long-term treatment with valproic acid and its
derivatives depletes the stores of carnitine, thus reducing
the metabolism of the drug and increasing the risk for
hyperammonemia [45, 53]. This condition is more common
in children less than 2 years of age, those with inborn errors
of metabolism and those patients on a vegetarian diet [22].
In patients with hyperammonemia, valproate levels may
often be normal and the symptoms do not necessarily
correlate with the degree of hyperammonemia, so clinical
correlation is paramount [24, 54, 55]. L-carnitine supple-
mentation has been shown to improve the symptoms of
valproate related toxicities and reduces mortality in patients
with valproate induced hepatotoxicity [56–58]. The use
of intravenous hydration, 60gm protein restriction, and
lactulose 45mL every 24 hours, in addition to stopping
the valproate has been shown to reduce valproic acid-
induced hepatotoxicity [58]. Monitoring of symptomatic
patients remains clinical rather than based on the serum
ammonia levels [12]. The primary treatment for most
patients with valproic acid-induced hyperammonemia is the
dose reduction or withdrawal of the oﬀending drug, in
which case, complete recovery often occurs within a few days
[4, 56]. Addition of L-carnitine supplementation to dose
reductionstrategiesmayaidinfasterresolutionofsymptoms
[8, 52].
6. Conclusion
In elderly patients, valproic acid-induced hyperammonemia
assumes signiﬁcance, as many of these patients have comor-
bid conditions that already decrease their quality of life [59].
With the growing use of valproic acid and other mood
stabilizersinthemanagementofpsychiatricconditionsinthe
elderly, it has become important for clinicians to be aware of
more uncommon adverse eﬀects of valproate.
A systematic review of literature indicates that there
are four case reports documenting the development of
hyperammonemia due to valproic acid and its derivatives
in the elderly. Three of the four cases developed when
valproate was used in the treatment of seizure disorder. The
fourth case occurred in an elderly man treated successfully
for bipolar illness with divalproex. As the mechanism of
valproate induced hyperammonemia is multifactorial, it is
important to be vigilant when using this medication in the
elderly patients who have many comorbid conditions and
concurrently use multiple drugs.4 Case Reports in Medicine
Although the followup of the blood ammonia levels
seems most intuitive in diagnosing hyperammonemia, often
patients with elevated ammonia levels are asymptomatic
[24, 54]. The data to recommend routine checking of
ammonialevelsinallelderlypatientstreatedwithvalproateis
unavailable. However, available data indicates that ammonia
levels should be checked and closely monitored in all elderly
patients treated with valproate who develop altered mental
status regardless of the duration of therapy and especially
during periods of acute illness [42]. The eﬃcacy of EEG
and imaging techniques like brain CT and MRI scans in
the diagnosis of symptomatic patients remains inconclusive
[14, 38].
From the review of literature it appears that the best
treatment measure for hyperammonemia from valproic acid
and its derivatives is the dose reduction or discontinuation
of the drug with or without supplementation of L-carnitine
and providing symptomatic treatment for the patient. In the
meantime, we should continue to carefully followup elderly
patients treated with valproate and its derivatives for the
development of sides eﬀects like hyperammonemia.
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